Allarity Therapeutics Inc. (ALLR) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Allarity Therapeutics Inc. (NASDAQ: ALLR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.87 (-2.20% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLR ranks #738 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALLR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OPTH (Optimi Health Corp.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $13.8M) and DARE (Dare Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, ALLR leads on earnings multiple (N/A) while ALLR leads on capital efficiency (-35.0% ROIC).
Per ALLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860657), Allarity Therapeutics Inc. generated $0 in revenue, -$11.2M in net income, and -$14.8M in free cash flow against $18.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ALLR currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.07) and Max Pain ($0.91) forces dealer call-delta covering toward $1.93.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Allarity Therapeutics Inc. (ALLR) dropped -2.20% to $0.87, trading at 9% of its 52-week range ($0.77 – $1.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
TipRanks report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
-SEC Filing
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALLR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALLR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Allarity Therapeutics Inc. (ALLR) ranks #738 by composite RQD confidence (32/100, grade E) and #860 by equity capitalization ($13.8M). Within this direct 5-issuer industry benchmark cohort, ALLR leads on earnings valuation at N/A trailing P/E, while ALLR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ALLR at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALLR
ACTIVE
Allarity Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -2.20% | $13.8M | Benchmark Subject |
| OPTH Optimi Health Corp. | D | 46/100 | — | — | — | -7.31% | $13.8M | /opth-vs-allr → |
| DARE Dare Bioscience Inc. | D- | 36/100 | — | 71.3% | -35.0% | +2.66% | $13.8M | /dare-vs-allr → |
| CTXR Citius Pharmaceuticals Inc. | D- | 40/100 | — | — | -35.0% | -7.10% | $14.4M | /ctxr-vs-allr → |
| NCEL NewcelX Ltd. | E | 28/100 | — | — | -35.0% | -5.27% | $14.7M | /ncel-vs-allr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allarity Therapeutics Inc. (ALLR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.2M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+16.0% YoY). On the balance sheet, ALLR closed FY2025 with $18.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$11.2M | -$14.8M | -$14.8M | $18.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.5M | -$17.4M | -$17.6M | $22.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.9M | -$12.7M | -$12.7M | — | — |
As of 2026-11-03, Allarity Therapeutics Inc. (NASDAQ: ALLR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.87 (-2.20% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLR ranks #738 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALLR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OPTH (Optimi Health Corp.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $13.8M) and DARE (Dare Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, ALLR leads on earnings multiple (N/A) while ALLR leads on capital efficiency (-35.0% ROIC).
Per ALLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860657), Allarity Therapeutics Inc. generated $0 in revenue, -$11.2M in net income, and -$14.8M in free cash flow against $18.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ALLR last traded at $0.87 (-2.20% on volume of 179,453 shares), positioning the stock -18.69% below its 50-day simple moving average ($1.07) and -28.10% below its 200-day simple moving average ($1.21). Across its 52-week range of $0.77 to $1.84, ALLR sits at the 9.3% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.98).
Why ALLR Stock dropped -2.20% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ALLR scores 31 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 4 out of 20, reflecting ROIC of -35% and FCF yield of 0%; for a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to support valuation. The whale 13F flow pillar scores 3 out of 20 (institutional accumulation and options positioning), suggesting weak institutional support in the source data. The insider conviction pillar scores 5 out of 20 (SEC Form 4 and Congressional PTR cluster flow), indicating limited insider-side confirmation. The macro regime fit pillar scores 9 out of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10 out of 20, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Taken together, the pillars point to deteriorating cash generation, weak ownership signals, and a constrained balance-sheet profile. Upside drivers in this framework are limited to the stock's depressed price and any future operational turnaround, which the source data does not establish; valuation multiples such as P/E and EV/EBITDA are not available in source data, so relative valuation cannot be assessed.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-12.6M | $-11.2M | N/A | $-14.8M | $14.7M | N/A |
| FY 2024 | $0.0M | $-27.2M | $-24.5M | N/A | $-17.6M | $19.5M | N/A |
| FY 2023 | $0.0M | $-17.1M | $-11.9M | N/A | $-12.7M | N/A | N/A |
Per the SEC financials, the company reported operating losses in all three periods and free cash flow outflows in each. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash declined from $19.5M to $14.7M between FY 2024 and FY 2025.
Per the news wire, recent items include: a Tumim stock purchase agreement ending ($6 million agreement, per headline); coverage describing resale coverage surviving the termination; and a first commercial CLIA laboratory services agreement described as a potential path to recurring revenue. Several items carry a YELLOW light and "MARKET WIRE" impact label. Risk watch items include the termination of the Tumim agreement and the company's zero reported revenue. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that the only sector context provided is the Health Care classification and a beta of 1.0.
Real-time company headlines, analyst actions, and sector developments for Allarity Therapeutics Inc. (ALLR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
TipRanks report covering Allarity Therapeutics Inc. (ALLR) market action, institutional positioning, and fundamental catalysts.
On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
Welcome to the ALLR (Allarity Therapeutics Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ALLR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Allarity Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ALLR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.89 (52-wk range $0.77 - $1.84), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).